Fig. 5

Epalrestat ameliorates LPS-induced NLRP3 inflammasome activation in vivo. A–E Mice were intraperitoneally injected with LPS or PBS for 6 h after pre-treatment with epalrestat or vehicle. ELISA of IL-1β A and TNF-α B in the serum and IL-1β C in the peritoneal lavage fluid was performed. Flow cytometric analysis of peritoneal cell exudates D–E. F-K Male or female mice were gavaged with epalrestat (120 mg/kg/day) or vehicle daily for 14 days. Changes in the body weight F, and AST G, ALT H, creatinine I, TBIL J, and glucose K levels were measured. Data are presented as the mean ± SD. Statistical differences were analyzed using an unpaired Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001; ns not significant